Generex Biotechnology Corporation: Introducing Revolutionary Cancer Immunotherapy While Redefining the Treatment for T1D, T2D

Related Quotes

SymbolPriceChange GNBT

0.71	+0.02

{"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""}

TORONTO, ONTARIO--(Marketwire - 01/14/10) - Generex Biotechnology Corporation (NASDAQ:GNBT - News) -

TheMarketFinancial.com, the news portal which covers the latest Wall Street developments while delivering financial and investment intelligence to a community of highly informed investors, has issued a special independent research coverage on Generex Biotechnology Corporation. (NASDAQ:GNBT - News)

This past year, small cap biotech investors were witness to some of the most profitable gains ever recorded in the stock market's history. The draw towards institutional and private investors searching for "FDA plays" has never been higher. "Generex has positioned itself to be the next target of high-risk, high-reward investors and institutions, as this upcoming year will prove to be the climax for the company," notes Michael Vlaicu of TheMarketFinancial. "With the recent contracting news regarding 7000 stores, and an initial $800,000 order for company's proprietary Crave-NX(TM) 7-Day Diet Aid Spra., a viable reoccurring revenue stream will now be present, thus paving the way for a much improved balance sheet on the eve of Oral-Lyn's NDA application and the beginning of AE37's Breast Cancer Immunotherapy Phase III trials, both of which are expected to take place sometime in Q3 or Q4 of this year."

Approval upon NDA submission is highly anticipated for Oral-Lyn (Type 1, Type 2 Diabetes oral insulin spray treatment) due to the fact that it has been accepted to be a part of USFDA's Treatment Investigational New Drug program. "Companies like Dendreon Corporation, Human Genome Sciences, and MannKind Corporation went from relatively unknown to being dominant market players, and Generex (NASDAQ:GNBT - News) has all the makings to be next in line." Generex's flagship product, Generex Oral-lyn(TM), an oral insulin spray for the treatment of diabetes, is approved for sale in India, Algeria, Lebanon and Ecuador, and is in Phase III clinical trials with over 347 patients being enrolled in 74 clinical sites around the world, including sites in the United States, Canada, Bulgaria, Poland, Romania, Russia and Ukraine. To read the company profile published by TheMarketFinancial, visit this link: http://www.themarketfinancial.com/introducing-revolutionary-cancer-immunotherapy-while-redefining-the-treatment-for-t1d-t2d-nasdaq-gnbt/1158